Skip to main content

Table 3 Patient demographics in the medical records review study

From: Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

 

Rounds 1 & 2

Round 3

Total

All patients

(N = 306)

(N = 131)

(N = 437)

Sex – male, n (%)

204 (66.7)

85 (64.9)

289 (66.1)

Age (years) – mean (SD)

66.4 (10.9)

64.3 (11.3)

65.8 (11.1)

  ≥ 65 years, n (%)

189 (61.8)

69 (52.7)

258 (59.0)

  ≥ 75 years, n (%)

73 (23.9)

27 (20.6)

100 (22.9)

Patients receiving concurrent oxaliplatina

(N = 85)

(N = 71)

(N = 156)

Sex – male, n (%)

65 (76.5)

49 (69.0)

114 (73.1)

Age (years) – mean (SD)

63.8 (11.2)

63.6 (10.1)

63.7 (10.6)

  ≥ 65 years, n (%)

48 (56.5)

33 (46.5)

81 (51.9)

  ≥ 75 years, n (%)

15 (17.6)

10 (14.1)

25 (16.0)

  1. SD standard deviation
  2. aReceived oxaliplatin-containing chemotherapy during the interval from 7 days before the date of the first dose of panitumumab until 7 days after the last dose of panitumumab